Miv Therapeutics, Inc. (IVT) Tops Q1 EPS by 2c, provides guidance

Miv Therapeutics, Inc. (NYSE: IVT) reported Q1 EPS of $0.09, $0.02 better than the analyst estimate of $0.07. Revenue for the quarter came in at $73.77 million versus the consensus estimate of $73.25 million.

GUIDANCE:

Miv Therapeutics, Inc. sees FY2025 EPS of $0.27-$0.33, versus the consensus of $0.29.

For earnings history and earnings-related data on Miv Therapeutics, Inc. (IVT) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Krait Critical Minerals closes $1.22M first tranche of placement
• KLX Energy narrows Q3 2026 revenue guidance, completes rights offering